Tag: Pharmaceuticals

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

Bicycle Therapeutics has entered into a 15-year agreement with the UK Nuclear Decommissioning Authority (NDA) to utilize reprocessed uranium from nuclear reactors for the...

On December 12, 2025, the U.S. health regulator went ahead and approved the oral antibiotic by Innoviva for treatment of gonorrhea, which is a...

Pfizer has confirmed that it has struck an almost $2.1bn licensing deal with YaoPharma in order to develop as well as commercialize its obesity...

The European Commission has stepped up and given the nod to €47 million in German state aid for Vetter Pharma, which is a German pharmaceutical service provider. The...

The European Council and European Parliament reached a provisional political agreement, on a comprehensive overhaul of the EU pharmaceutical legislation, the first major reform...